CD40L Inhibitor Frexalimab to be Tested in Phase 3 Trials of Relapsing MS and Non-Relapsing Secondary Progressive MS; The phase 3 trials are expected to assess the therapeutic potential of frexalimab dosed every 4 weeks in both patients with relapsing MS

Media coverage

• Title	CD40L Inhibitor Frexalimab to be Tested in Phase 3 Trials of Relapsing MS and Non-Relapsing Secondary Progressive MS; The phase 3 trials are expected to assess the therapeutic potential of frexalimab dosed every 4 weeks in both patients with relapsing MS
  Media name/outlet	Neurology Live
  Country/Territory	United States
  Date	1/06/24
  Persons	Stephen C. Krieger